Investment memo
Science Corporation
Science develops technologies to transcend the limits of biology.
United StatesInformation updated on Aug 7, 2026
Unicorn scoreA 100-point read across the founding team, traction, market, execution and how well each is evidenced. Higher means closer to the profile of companies that went on to reach a billion-dollar valuation.
Current valuation
$1.5B
Verified Aug 4, 2026
First screened
Aug 4, 2026
Total raised
$490M
Last round: Series C
Addressable market
$200B
Global Smart Medical Devices Market
Science Corporation is a clinical-stage medical technology company focused on neural engineering solutions. The company develops advanced devices to restore vision, cognition, and mobility for patients with debilitating conditions lacking treatment options. Additionally, Science Corporation provides state-of-the-art components and vertically integrated infrastructure through Science Foundry to support broader industry progress.
How the score breaks down
A 100-point read across the founding team, traction, market, execution and how well each is evidenced. Higher means closer to the profile of companies that went on to reach a billion-dollar valuation.| Category | Strength | Score |
|---|---|---|
| Founder Background | 84% | |
| Strategic Position | 90% | |
| Execution Velocity | 87% | |
| Traction Momentum | 45% | |
| Market & Scalability | 93% |
Data confidence 81/100. This measures how much of the memo rests on sourced evidence rather than inference. It was assembled by reading 113 public sources about the company. Compiled Aug 7, 2026.
That gathering is automated, so mistakes are possible. The confidence figure is the honest guide: the higher it is, the more of what you are reading came from a source rather than an inference.
Founding team
Prior exits, repeat founders and relevant domain experience are the single strongest early signal in venture data.2 founders · 1 repeat founder
Max Hodak
Founder and CEO
Repeat founderSerial entrepreneur. Founded Neuralink.
Previously worked at
- Neuralink (Co-founder)
Education
- Duke University - Biomedical Engineering
- Duke University - Neuroscience
Alan Mardinly
Co-founder, Chief Scientific Officer
Stanford University, PhD Neuroscience.
Previously worked at
- Neuralink (Director of Research)
Education
- Stanford University - PhD Neuroscience
Traction
- Latest round
- Series C · $230M
- Revenue
- $150K
- Estimated, not a filing
- Team size
- 317
Investors (5)
Momentum & social pulse
Momentum & social pulse- Press coverage
- +3 articles
- vs the 3 months before
- LinkedIn followers
- 15.9K
- LinkedIn activity
- 34.3 posts / 30 days
- last post 0 days ago
Market
Why this startup makes sense now
What changed in the world recently that makes this the right moment. A great idea at the wrong time still fails, so a weak answer here is a real risk.Clinical validation and EU regulatory approval (CE Mark) of the PRIMA retinal implant, confirmed by an NEJM editorial as the first treatment to restore vision for Geographic Atrophy, enabling its commercial launch in Europe in mid-2026.
What competitors cannot copy
What the company has that a well-funded competitor cannot simply copy: proprietary technology, exclusive data, a regulatory position, a network that grows with every user.Science Corporation's unfair advantage stems from its proprietary, vertically-integrated, full-stack neural engineering platform, specifically the PRIMA retinal implant. This technology has achieved clinical validation and EU regulatory approval, positioning it as the world's first and only treatment to restore functional central vision for Geographic Atrophy, creating a significant first-mover and regulatory moat.
Who else is in the race
Who else is going after the same customers, and where this company sits among them.Competitive landscape data not available from public sources.
Path to a billion
The arithmetic that gets to a billion-dollar outcome: who they sell to, at what price, and how many of them there need to be.Science Corporation's path to $1B revenue hinges on the successful global commercialization of its PRIMA retinal implant, currently the only treatment restoring functional central vision for Geographic Atrophy. Following its European launch, scaling involves securing regulatory approvals and market penetration in key regions like the US and Asia. Leveraging its full-stack neural engineering platform and first-mover advantage, the company can expand its BCI pipeline to address other neurological conditions, capturing significant market share in the rapidly growing smart medical devices sector.
Our track record on this company
The valuation recorded the first time this company was screened, against the most recent verified one. It is never rewritten, so the multiple is a real track record.| First screened | Aug 4, 2026 |
|---|---|
| Entry valuation | $1.5B |
| Current valuation | $1.5B |
Latest valuation verified from Live re-screening on Aug 4, 2026. Entry valuation and date are frozen the first time a company is screened and are never rewritten. Valuations are re-checked quarterly against public funding announcements.
More startups in HealthTech
Each one carries a memo like this, built the same way and scored on the same 100 points.
How this works
Screen the next one yourself
Every startup on the board has a memo like this one. Your first screening is free, and there is no account to create.